Aug. 23 at 4:12 PM
$PTIX
I believe one reason the stock has remained stable this time, unlike previous spikes that were followed by immediate drops, is the announcement that the dosing will be completed by the end of August, with results expected at the end of September. This provides little time for investors to position themselves ahead of the news. The stock was significantly oversold, and those looking to invest before the September news likely want to secure shares at any price up to
$7. Even after the recent spike, the price remains very low, making it a good entry point for investors. If positive news is released by the end of September, I expect the stock to retest its highs for the year, potentially exceeding
$14.
